a public good project by the
Synthesis
Company
of California

© 2026

Cheng‐Yuan Peng | doi.page

0 works0 citations0 h-index

Cheng‐Yuan Peng

China Medical University(TW)China Medical University Hospital(TW)

Publications by Year

Research Areas

Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease and Transplantation

Most-Cited Works

→ Mitotic and G ₂ Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216(1997)1,329 cited
→ SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma(2018)635 cited
→ Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy(2016)362 cited
→ All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study(2014)343 cited
→ Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.(1994)284 cited
→ Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study(2011)228 cited

→ Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy(2012)

221 cited

→ Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients(2016)219 cited

→ Omega-3 Fatty Acids in the Prevention of Interferon-Alpha-Induced Depression: Results from a Randomized, Controlled Trial(2014)201 cited

→ Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis(2000)188 cited